Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Dynavax Technologies's Business Segments
Dynavax Technologies's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
10
Largest Segment
Reportable Segments
Total Revenue
$ 95
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reportable Segments100%
- U S99.8%
- HEPLISAV-B94.8%
- HEPLISAV-B U S94.8%
- Product revenue net94.8%
- Product revenue net U S94.8%
- Other revenue5.2%
- Other revenue U S5%
- Other revenue Non U S0.2%
- Non U S0.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segments | $ 95 | 100% |
| U S | $ 95 | 99.8% |
| HEPLISAV-B | $ 90 | 94.8% |
7 more segments available
Sign in to unlock the full Dynavax Technologies dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Reportable Segments100%
- U S99.8%
- HEPLISAV-B94.8%
- HEPLISAV-B U S94.8%
- Product revenue net94.8%
- Product revenue net U S94.8%
- Other revenue5.2%
- Other revenue U S5%
- Other revenue Non U S0.2%
- Non U S0.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segments | $ 95 | 100% |
| U S | $ 95 | 99.8% |
| HEPLISAV-B | $ 90 | 94.8% |
7 more segments available
Sign in to unlock the full Dynavax Technologies dataset.
Description of Dynavax Technologies
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company that develops and commercializes novel vaccines and therapeutics to prevent infectious diseases, cancer, and chronic inflammatory diseases. The company is headquartered in Emeryville, California, and was founded in 199
Dynavax's proprietary technology platforms include the Toll-like Receptor (TLR) and the C-Class CpG deoxyribonucleic acid (CpG DNA) technologies. These platforms stimulate the innate immune system and enhance the body's immune response to various pathogens and tumor antigens.
The company's lead product candidate is HEPLISAV-B, which is an adult hepatitis B vaccine designed to provide faster and more effective protection against hepatitis B compared to traditional vaccines. HEPLISAV-B was approved by the US Food and Drug Administration (FDA) in November 201
Dynavax is also developing SD-101, an investigational TLR9 agonist in phase 3 clinical trials for the treatment of advanced melanoma in combination with Keytruda. The company is also developing DV281, an investigational TLR7/8 agonist in phase 1 clinical trials for the treatment of non-small cell lung cancer.
In addition, Dynavax has partnerships and collaborations with several leading pharmaceutical companies and organizations, including AstraZeneca, GlaxoSmithKline, and the Bill & Melinda Gates Foundation.
Dynavax has a strong financial position, with a market capitalization of approximately $5 billion as of September 202 The company's total revenue for the second quarter of 2021 was $28.1 million, compared to $0 million for the same period in 2020. The company's net loss for the second quarter of 2021 was $68.7 million, compared to $31 million for the same period in 2020.
Overall, Dynavax Technologies Corp is a leading biopharmaceutical company with a promising pipeline of innovative vaccines and therapeutics for the prevention and treatment of infectious and chronic diseases. The company's unique technology platforms and strategic partnerships position it well for continued success in the biopharmaceutical industry.
Dynavax's proprietary technology platforms include the Toll-like Receptor (TLR) and the C-Class CpG deoxyribonucleic acid (CpG DNA) technologies. These platforms stimulate the innate immune system and enhance the body's immune response to various pathogens and tumor antigens.
The company's lead product candidate is HEPLISAV-B, which is an adult hepatitis B vaccine designed to provide faster and more effective protection against hepatitis B compared to traditional vaccines. HEPLISAV-B was approved by the US Food and Drug Administration (FDA) in November 201
Dynavax is also developing SD-101, an investigational TLR9 agonist in phase 3 clinical trials for the treatment of advanced melanoma in combination with Keytruda. The company is also developing DV281, an investigational TLR7/8 agonist in phase 1 clinical trials for the treatment of non-small cell lung cancer.
In addition, Dynavax has partnerships and collaborations with several leading pharmaceutical companies and organizations, including AstraZeneca, GlaxoSmithKline, and the Bill & Melinda Gates Foundation.
Dynavax has a strong financial position, with a market capitalization of approximately $5 billion as of September 202 The company's total revenue for the second quarter of 2021 was $28.1 million, compared to $0 million for the same period in 2020. The company's net loss for the second quarter of 2021 was $68.7 million, compared to $31 million for the same period in 2020.
Overall, Dynavax Technologies Corp is a leading biopharmaceutical company with a promising pipeline of innovative vaccines and therapeutics for the prevention and treatment of infectious and chronic diseases. The company's unique technology platforms and strategic partnerships position it well for continued success in the biopharmaceutical industry.
Dynavax Technologies Corporation is a biopharmaceutical company that focuses on developing innovative products aimed at lowering the risk and protecting against infectious diseases, allergies, and cancer. The companys operations are concentrated in the biopharmaceutical development segment, where it emphasizes transforming scientific advancements into new medicines that enhance human health and improve patient quality of life. The company primarily targets areas with substantial unmet medical needs, underpinned by a robust research and development strategy centered on vaccines and immuno-oncology.
Segments
Biopharmaceutical Development:
Dynavax operates within a single business segment, Biopharmaceutical Development. This area encompasses the company’s comprehensive research initiatives, clinical trial management, regulatory affairs, and interactions with healthcare providers. The companys commitment to advancing medical science drives its efforts in creating innovative therapeutic solutions that address serious health issues, particularly in the realms of infectious diseases and oncology.
Products
1. HEPLISAV-B:
- Overview: Dynavaxs flagship product, HEPLISAV-B, is a novel hepatitis B vaccine designed to provide efficient and durable protection against the hepatitis B virus.
- Indication: It serves as a preventative measure for individuals at risk of hepatitis B infection, including healthcare workers and people with certain lifestyle factors.
- Approval & Availability: The vaccine has received regulatory approval in multiple regions, including the United States and Europe, allowing healthcare providers to administer it widely.
2. SD-101:
- Overview: SD-101 is an investigational drug that acts as a TLR9 agonist formulated for the treatment of advanced melanoma.
- Mechanism: As a TLR9 agonist, it plays a vital role in stimulating the immune system, which may enhance the body’s ability to recognize and eliminate cancer cells.
- Clinical Status: This product candidate is undergoing various stages of clinical trials to assess its safety and efficacy in patients with advanced melanoma.
3. DV281:
- Overview: DV281 is another promising product candidate in Dynavaxs portfolio, designed as a TLR7/8 agonist aimed at treating solid tumors.
- Mechanism: By activating specific toll-like receptors, DV281 is expected to trigger immune responses that can potentially inhibit tumor growth and improve treatment outcomes.
- Clinical Development: Currently, DV281 is in phase 1 clinical trials, where it is being evaluated for its safety and biological activity in patients with solid tumors.
4. AZD1419:
- Overview: AZD1419 is a collaborative product developed in partnership with AstraZeneca, targeting the treatment of asthma as a TLR9 agonist.
- Mechanism: This candidate aims to modulate the immune response in asthmatic patients, with the potential to reduce exacerbations and improve respiratory function.
- Clinical Development: It is currently progressing through phase 2 clinical trials, where its efficacy and safety are being closely monitored.
Services
Dynavax Technologies Corporation primarily focuses on the research and development of critical healthcare solutions. Its services are centered around:
- Research and Development: The core service at Dynavax entails extensive research activities designed to innovate and optimize therapeutic candidates. This includes preclinical studies and multiple phases of clinical trials to gather data supporting product efficacy and safety.
- Partnerships and Collaborations: Through strategic alliances with other pharmaceutical companies and academic institutions, Dynavax enhances its research capabilities and accelerates the path to market for its therapeutic products. These collaborations often involve shared expertise and resources to foster innovation in drug development.
- Education and Training: Dynavax also offers training and educational resources to healthcare providers regarding the administration and best practices related to their vaccines. This service aims to ensure that medical professionals are well-equipped with the necessary knowledge to maximize patient outcomes through effective vaccination strategies.
In summary, Dynavax Technologies Corporation embodies a commitment to advancing human health through the development of groundbreaking biopharmaceutical products while providing essential services that enhance the delivery and efficacy of its therapeutic innovations.
Segments
Biopharmaceutical Development:
Dynavax operates within a single business segment, Biopharmaceutical Development. This area encompasses the company’s comprehensive research initiatives, clinical trial management, regulatory affairs, and interactions with healthcare providers. The companys commitment to advancing medical science drives its efforts in creating innovative therapeutic solutions that address serious health issues, particularly in the realms of infectious diseases and oncology.
Products
1. HEPLISAV-B:
- Overview: Dynavaxs flagship product, HEPLISAV-B, is a novel hepatitis B vaccine designed to provide efficient and durable protection against the hepatitis B virus.
- Indication: It serves as a preventative measure for individuals at risk of hepatitis B infection, including healthcare workers and people with certain lifestyle factors.
- Approval & Availability: The vaccine has received regulatory approval in multiple regions, including the United States and Europe, allowing healthcare providers to administer it widely.
2. SD-101:
- Overview: SD-101 is an investigational drug that acts as a TLR9 agonist formulated for the treatment of advanced melanoma.
- Mechanism: As a TLR9 agonist, it plays a vital role in stimulating the immune system, which may enhance the body’s ability to recognize and eliminate cancer cells.
- Clinical Status: This product candidate is undergoing various stages of clinical trials to assess its safety and efficacy in patients with advanced melanoma.
3. DV281:
- Overview: DV281 is another promising product candidate in Dynavaxs portfolio, designed as a TLR7/8 agonist aimed at treating solid tumors.
- Mechanism: By activating specific toll-like receptors, DV281 is expected to trigger immune responses that can potentially inhibit tumor growth and improve treatment outcomes.
- Clinical Development: Currently, DV281 is in phase 1 clinical trials, where it is being evaluated for its safety and biological activity in patients with solid tumors.
4. AZD1419:
- Overview: AZD1419 is a collaborative product developed in partnership with AstraZeneca, targeting the treatment of asthma as a TLR9 agonist.
- Mechanism: This candidate aims to modulate the immune response in asthmatic patients, with the potential to reduce exacerbations and improve respiratory function.
- Clinical Development: It is currently progressing through phase 2 clinical trials, where its efficacy and safety are being closely monitored.
Services
Dynavax Technologies Corporation primarily focuses on the research and development of critical healthcare solutions. Its services are centered around:
- Research and Development: The core service at Dynavax entails extensive research activities designed to innovate and optimize therapeutic candidates. This includes preclinical studies and multiple phases of clinical trials to gather data supporting product efficacy and safety.
- Partnerships and Collaborations: Through strategic alliances with other pharmaceutical companies and academic institutions, Dynavax enhances its research capabilities and accelerates the path to market for its therapeutic products. These collaborations often involve shared expertise and resources to foster innovation in drug development.
- Education and Training: Dynavax also offers training and educational resources to healthcare providers regarding the administration and best practices related to their vaccines. This service aims to ensure that medical professionals are well-equipped with the necessary knowledge to maximize patient outcomes through effective vaccination strategies.
In summary, Dynavax Technologies Corporation embodies a commitment to advancing human health through the development of groundbreaking biopharmaceutical products while providing essential services that enhance the delivery and efficacy of its therapeutic innovations.